Reticular’s current public product is reproductive-gene screening. Its older YC material describes a different, earlier research direction, so the transition matters.
What it does now
The current Reticular website sells an at-home saliva panel for people planning a pregnancy, navigating infertility or looking for more information after recurrent pregnancy loss. The company says it screens 750+ reproductive genes, sends a kit to one or both partners, and includes genetic-counselor review. It also presents embryo reports for people who already have compatible embryo data.
The current purchase path is concrete: one-partner testing is listed at $250 and testing both partners at $500. The site says results are typically expected about three weeks after the sample reaches the lab, and it publishes a no-reportable-finding refund policy with eligibility terms. These are company-stated product terms, not a medical recommendation or independent clinical evaluation.
The important context
The YC profile and its linked launch material describe Reticular as genomic AI for embryo selection and a protein-engineering research platform. The current homepage is a consumer reproductive-genetics product. I would not merge the old protein-design story into the current buyer pitch. The better reading is that the company’s public product and positioning have moved toward a direct-to-consumer reproductive-health workflow.
The public page is unusually clear about the human boundary. A report is presented as information to review with a genetic counselor and care team, not a diagnosis or treatment plan. That distinction is essential in a health product.
My editorial take
Shortlist Reticular if you want a clearly priced at-home screening path with counseling included and you understand that the result needs clinical context. It is not a replacement for a fertility evaluation, and the current site does not claim that a finding predicts whether someone will conceive. The strongest product decision is the handoff: the company sells a test and an explanation, then leaves medical decisions with the care team.
Quick facts
| Field | Sourced detail |
|---|---|
| Current product | At-home reproductive-gene screening and embryo reports |
| Buyer | People planning pregnancy, navigating infertility or recurrent loss |
| Price | $250 for one partner; $500 for both |
| Process | Saliva kit → lab screening → report → genetic-counselor conversation |
| Important boundary | Company says the report is information to discuss, not a diagnosis or treatment plan |
Sources checked
| Source | Checked |
|---|---|
| YC company profile | 2026-09-19 |
| Reticular homepage | 2026-09-19 |
| Reticular pricing | 2026-09-19 |
| No-finding eligibility terms | 2026-09-19 |
Cohort context
Reticular is listed in Fall 2024. In our 2026-09-18 directory snapshot, 9 of 94 listed companies in that cohort have YC’s primary industry label Healthcare (9.6%). This is a current-directory comparison, not an original intake count or a performance ranking. Nine-cohort dataset.
Public website snapshot
Observed 2026-09-19 16:14 UTC in raw homepage HTML. This records visible metadata and advertised links, not agent execution or product quality.
| Signal | Homepage observation |
|---|---|
| Product description metadata | Observed |
| Canonical link | Observed |
| H1 or H2 heading | Observed |
| Typed structured data | Observed |
| Docs/developer link | Not observed in this response |
| Pricing link | Observed |
| llms.txt link | Not observed in this response |
| Markdown alternate | Not observed in this response |
Public observations · Collection method. Missing links here do not establish that a capability or file is absent elsewhere.
